{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:09Z","timestamp":1787995029797,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bilimsel Ara\u015ft\u0131rma Projeleri Birimi, \u0130stanbul \u00dcniversitesi , T\u00fcrkiye"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12562-8","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:38:35Z","timestamp":1787992715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-5709","authenticated-orcid":false,"given":"Demet","family":"Kivanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-1394","authenticated-orcid":false,"given":"Selcuk","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8158","authenticated-orcid":false,"given":"Ozge","family":"Hurdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-482X","authenticated-orcid":false,"given":"Hayriye Senturk","family":"Ciftci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-0488","authenticated-orcid":false,"given":"Yasemin","family":"Ozluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6898","authenticated-orcid":false,"given":"Oner","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-1026","authenticated-orcid":false,"given":"Meltem Savran","family":"Karadeniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-9941","authenticated-orcid":false,"given":"Isin","family":"Kilicaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-8936","authenticated-orcid":false,"given":"Fatma","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"1","key":"12562_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"12562_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2022.01.075","volume":"33","author":"M Moschini","year":"2022","unstructured":"Moschini M, Gandaglia G, Deh\u00f2 F et al (2022) Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(5):561. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.075","journal-title":"Ann Oncol"},{"issue":"6","key":"12562_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M et al (2022) Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol 5(6):628\u201339. https:\/\/doi.org\/10.1016\/j.euo.2022.10.003","journal-title":"Eur Urol Oncol"},{"issue":"17","key":"12562_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176072","volume":"21","author":"T Hayashi","year":"2020","unstructured":"Hayashi T, Fujita K, Hayashi Y et al (2020) Mutational landscape and environmental effects in bladder cancer. Int J Mol Sci 21(17):6072. https:\/\/doi.org\/10.3390\/ijms21176072","journal-title":"Int J Mol Sci"},{"issue":"6","key":"12562_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.gendis.2020.10.002","volume":"8","author":"X Huang","year":"2020","unstructured":"Huang X, Pan T, Yan L et al (2020) The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer. Genes Dis 8(6):781\u2013797. https:\/\/doi.org\/10.1016\/j.gendis.2020.10.002","journal-title":"Genes Dis"},{"issue":"4","key":"12562_CR6","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e31","volume":"24","author":"M Naskar","year":"2024","unstructured":"Naskar M, Choi HW (2024) A dynamic interplay of innate immune responses during urinary tract infection. Immune Netw 24(4):e31. https:\/\/doi.org\/10.4110\/in.2024.24.e31","journal-title":"Immune Netw"},{"issue":"4","key":"12562_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.18053\/jctres.07.202104.009","volume":"30","author":"Z Yang","year":"2021","unstructured":"Yang Z, Xu Y, Bi Y et al (2021) Immune escape mechanisms and immunotherapy of urothelial bladder cancer. J Clin Transl Res 30(4):485\u2013500","journal-title":"J Clin Transl Res"},{"issue":"1","key":"12562_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12672-025-02509-z","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Tang T, Sun Y et al (2025) The role of TLR-4 in chemoresistance of cancer. Discov Onc 16(1):865. https:\/\/doi.org\/10.1007\/s12672-025-02509-z","journal-title":"Discov Onc"},{"key":"12562_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.651560","volume":"9","author":"JL Lu","year":"2021","unstructured":"Lu JL, Xia QD, Sun Y et al (2021) Toll-like receptor 4 as a favorable prognostic marker in bladder cancer: a multi-omics analysis. Front Cell Dev Biol 9:651560. https:\/\/doi.org\/10.3389\/fcell.2021.651560","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"12562_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12964-024-01957-4","volume":"22","author":"M Liaghat","year":"2024","unstructured":"Liaghat M, Ferdousmakan S, Mortazavi SH et al (2024) The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal 22(1):575. https:\/\/doi.org\/10.1186\/s12964-024-01957-4","journal-title":"Cell Commun Signal"},{"issue":"20","key":"12562_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells14201594","volume":"14","author":"AL Shakerdi","year":"2025","unstructured":"Shakerdi AL, Finnegan E, Sheng YY et al (2025) Crosstalk between inflammasome signalling and epithelial-mesenchymal transition in cancer and benign disease: mechanistic insights, context-dependence, and therapeutic opportunities. Cells 14(20):1594. https:\/\/doi.org\/10.3390\/cells14201594","journal-title":"Cells"},{"issue":"2","key":"12562_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.21873\/anticanres.13166","volume":"39","author":"Y Kusuhara","year":"2019","unstructured":"Kusuhara Y, Daizumoto K, Kawai K et al (2019) Low Expression of Toll-like Receptor 4 Is Associated with Poor Prognosis in Bladder Cancer. Anticancer Res 39(2):703\u2013711. https:\/\/doi.org\/10.21873\/anticanres.13166","journal-title":"Anticancer Res"},{"key":"12562_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.965231","volume":"12","author":"K Klicka","year":"2022","unstructured":"Klicka K, Grzywa TM, Mielniczuk A et al (2022) The role of miR-200 family in the regulation of hallmarks of cancer. Front Oncol 12:965231. https:\/\/doi.org\/10.3389\/fonc.2022.965231","journal-title":"Front Oncol"},{"key":"12562_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01053","volume":"14","author":"R Bayraktar","year":"2019","unstructured":"Bayraktar R, Bertilaccio MTS, Calin GA (2019) The interaction between two worlds: microRNAs and Toll-like receptors. Front Immunol 14:1053. https:\/\/doi.org\/10.3389\/fimmu.2019.01053","journal-title":"Front Immunol"},{"issue":"5","key":"12562_CR15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.12.097","volume":"185","author":"C Ayari","year":"2011","unstructured":"Ayari C, Bergeron A, LaRue H et al (2011) Toll-like receptors in normal and malignant human bladders. J Urol 185(5):1915\u20131921. https:\/\/doi.org\/10.1016\/j.juro.2010.12.097","journal-title":"J Urol"},{"issue":"2","key":"12562_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.32471\/exp-oncology.2312-8852.vol-43-no-2.16102","volume":"43","author":"PG Yakovlev","year":"2021","unstructured":"Yakovlev PG, Gorbach OI, Ostapchenko LI et al (2021) Expression of TLR4 and major inflammatory cytokines in patients with bladder cancer of different grade and stage. Exp Oncol 43(2):142\u2013148. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-43-no-2.16102","journal-title":"Exp Oncol"},{"key":"12562_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-44518-8_9","volume-title":"Tumor Microenvironment. Advances in Experimental Medicine and Biology","author":"M Angrini","year":"2020","unstructured":"Angrini M, Varthaman A, Cremer I (2020) Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. In: Birbrair A (ed) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1263. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-030-44518-8_9."},{"issue":"3","key":"12562_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/cancers17030529","volume":"17","author":"R Kanwal","year":"2025","unstructured":"Kanwal R, Esposito JE, Jawed B et al (2025) Exploring the Role of Epithelial\u2013Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review. Cancers 17(3):529. https:\/\/doi.org\/10.3390\/cancers17030529","journal-title":"Cancers"},{"issue":"4","key":"12562_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11033-017-4118-z","volume":"44","author":"S Hussein","year":"2017","unstructured":"Hussein S, Mosaad H, Rashed HE et al (2017) Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features. Mol Biol Rep 44(4):365\u2013377. https:\/\/doi.org\/10.1007\/s11033-017-4118-z","journal-title":"Mol Biol Rep"},{"issue":"3","key":"12562_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/15321819.2024.2335154","volume":"45","author":"S Ben Rejeb","year":"2024","unstructured":"Ben Rejeb S, Kouki N, Ben Ghachem D et al (2024) Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer. J Immunoass Immunochem 45(3):261\u2013270. https:\/\/doi.org\/10.1080\/15321819.2024.2335154","journal-title":"J Immunoass Immunochem"},{"issue":"18","key":"12562_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T et al (2021) Dynamic EMT: a multi-tool for tumor progression. EMBO J 40(18):e108647. https:\/\/doi.org\/10.15252\/embj.2021108647","journal-title":"EMBO J"},{"issue":"1","key":"12562_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tcb.2022.08.002","volume":"33","author":"A Zabini","year":"2023","unstructured":"Zabini A, Zimmer Y, Medov\u00e1 M (2023) Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins. Trends Cell Biol 33(1):5\u20138. https:\/\/doi.org\/10.1016\/j.tcb.2022.08.002","journal-title":"Trends Cell Biol"},{"key":"12562_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2024.101967","volume":"76","author":"Y Zhen","year":"2024","unstructured":"Zhen Y, Li X, Huang S et al (2024) LncRNA lnc-SPRR2G-2 contributes to keratinocyte hyperproliferation and inflammation in psoriasis by activating the STAT3 pathway and downregulating KHSRP. Mol Cell Probes 76:101967. https:\/\/doi.org\/10.1016\/j.mcp.2024.101967","journal-title":"Mol Cell Probes"},{"issue":"1","key":"12562_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s42003-024-06864-5","volume":"16","author":"X Xuanyuan","year":"2024","unstructured":"Xuanyuan X, Zhang L, Zheng Y et al (2024) SPRR1B+ keratinocytes prime oral mucosa for rapid wound healing via STAT3 activation. Commun Biol 16(1):1155. https:\/\/doi.org\/10.1038\/s42003-024-06864-5","journal-title":"Commun Biol"},{"key":"12562_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2024.101926","volume":"36","author":"RK Chaudhary","year":"2024","unstructured":"Chaudhary RK, Patil P, Shetty VV et al (2024) Decoding the role of SPRR1A and SPRR1B gene in cancer: a comprehensive review. Gene Rep 36:101926. https:\/\/doi.org\/10.1016\/j.genrep.2024.101926","journal-title":"Gene Rep"},{"issue":"9","key":"12562_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41585-024-00886-8","volume":"21","author":"B Czerniak","year":"2024","unstructured":"Czerniak B (2024) Bladder cancer variants \u2014 one disease with many faces. Nat Rev Urol 21(9):519\u2013520. https:\/\/doi.org\/10.1038\/s41585-024-00886-8","journal-title":"Nat Rev Urol"},{"issue":"2","key":"12562_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11033-010-0205-0","volume":"38","author":"N Varol","year":"2011","unstructured":"Varol N, Konac E, Gurocak OS et al (2011) The realm of microRNAs in cancers. Mol Biol Rep 38(2):1079\u20131089. https:\/\/doi.org\/10.1007\/s11033-010-0205-0","journal-title":"Mol Biol Rep"},{"issue":"14","key":"12562_CR28","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.7150\/ijbs.47203","volume":"16","author":"B He","year":"2020","unstructured":"He B, Zhao Z, Cai Q et al (2020) miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 16(14):2628\u20132647. https:\/\/doi.org\/10.7150\/ijbs.47203","journal-title":"Int J Biol Sci"},{"issue":"4","key":"12562_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3892\/ol.2026.15484","volume":"31","author":"M Senturk","year":"2026","unstructured":"Senturk M, Gumusoglu-Acar E, Topuz S et al (2026) Effect of the hsa-microRNA 200c-3p\/ZEB1 loop in epithelial-mesenchymal transition of ovarian cancer cells. Oncol Lett 31(4):131. https:\/\/doi.org\/10.3892\/ol.2026.15484","journal-title":"Oncol Lett"},{"issue":"4","key":"12562_CR30","first-page":"519","volume":"50","author":"H Chen","year":"2020","unstructured":"Chen H, Li Z, Zhang L et al (2020) MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator. Ann Clin Lab Sci 50(4):519\u2013527","journal-title":"Ann Clin Lab Sci"},{"issue":"6","key":"12562_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s11255-022-03173-w","volume":"54","author":"X Zhao","year":"2022","unstructured":"Zhao X, Wang Y, Liang C (2022) Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis. Int Urol Nephrol 54(6):1169\u20131185. https:\/\/doi.org\/10.1007\/s11255-022-03173-w","journal-title":"Int Urol Nephrol"},{"key":"12562_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/03946320231166774","volume":"37","author":"Y Ling","year":"2023","unstructured":"Ling Y, Li J, Zhou L (2023) Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer. Int J Immunopathol Pharmacol 37:3946320231166774. https:\/\/doi.org\/10.1177\/03946320231166774","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"12562_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3892\/etm.2022.11552","volume":"24","author":"Y Li","year":"2022","unstructured":"Li Y, Tan S, Shen Y et al (2022) miR\u2013146a\u20135p negatively regulates the IL\u20131\u03b2\u2013stimulated inflammatory response via downregulation of the IRAK1\/TRAF6 signaling pathway in human intestinal epithelial cells. Experimental therapeutic Med 24(4):615. https:\/\/doi.org\/10.3892\/etm.2022.11552","journal-title":"Experimental therapeutic Med"},{"key":"12562_CR34","doi-asserted-by":"publisher","first-page":"112115","DOI":"10.1016\/j.cellsig.2025.112115","volume":"136","author":"M Alimohammadi","year":"2025","unstructured":"Alimohammadi M, Amani D, Adcock IM (2025) Dual role of mir-146a in non-small cell lung cancer progression: Molecular mechanisms and clinical potential. Cell Signal 136:112115. https:\/\/doi.org\/10.1016\/j.cellsig.2025.112115","journal-title":"Cell Signal"},{"key":"12562_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215615","volume":"534","author":"R Yan","year":"2022","unstructured":"Yan R, Dai W, Wu R et al (2022) Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Lett 534:215615. https:\/\/doi.org\/10.1016\/j.canlet.2022.215615","journal-title":"Cancer Lett"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12562-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:38:36Z","timestamp":1787992716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12562-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12562"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12562-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Scientific Research Project Board of Istanbul University (Project No: 39194- TDK-2022-39194).","order":3,"name":"Ethics","label":"Financial Support","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study received approval from by the \u201cClinical Research Ethics Committee of Istanbul University\u201d (approval date: 06.07.2022, protocol number: 2022\/1050) and the research followed the ethical standards outlined in the \u201cDeclaration of Helsinki\u201d.","order":4,"name":"Ethics","label":"Ethics committee approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants.","order":5,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1489"}}